Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2410)	6/10/2005 5:15:17 PM
From: Ian@SI	Read Replies (1) \| Respond to of 3044

Thanks for digging up the abstract. Velcade seems to have much untapped potential. ... or at least proteasome inhibition. From the JNJ PR a couple weeks ago, they remain quite optimistic. ... Another promising drug, executives said, is Velcade, a cancer drug licensed from Millennium Pharmaceuticals Inc. (MLNM), which is currently used to treat multiple myeloma. Johnson & Johnson is studying expanding its use for the treatment of non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer and prostate cancer.